Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2022

Equity [Abstract]

Share-Based Compensation Expense

Stock-based compensation expense recognized during the three and nine months ended September 30, 2022 and 2021 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. No stock-based compensation costs were capitalized during the three and nine months ended September 30, 2022 and 2021.

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2022		2021		2022		2021
Cost of revenue:
Provider	$	283	$	213	$	821	$	709
Payer & Life Sciences		46		52		71		158
Total cost of revenue		329		265		892		867
Selling, general and administrative expenses		3,831		2,079		17,629		6,967
Research and development		552		828		2,278		2,834
Total stock-based compensation expense	$	4,712	$	3,172	$	20,799	$	10,668

Share-Based Awards Granted

We granted stock-based awards as follows:

	Three Months Ended September 30, 2022				Nine Months Ended September 30, 2022
			Weighted-Average				Weighted-Average
			Grant Date				Grant Date
(In thousands, except per share amounts)	Shares		Fair Value		Shares		Fair Value
Service-based restricted stock units		14	$	15.82		1,260	$	18.41
Performance-based restricted stock units with a service condition		0	$	0.00		243	$	18.56
Market-based restricted stock units with a service condition		0	$	0.00		258	$	21.90
		14	$	15.82		1,761	$	18.94